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1 Background 
The extraordinary high amount of 20-25 billion Euros of annual turnover in 
the Austrian health system has increasingly raised the questions of cost-
effectiveness and evidence based decision making in health care. Health 
technology assessment is already intensively dealing with these issues, espe-
cially on the level of single interventions. Still, due to lack of data, assess-
ments often include modelling or simulation techniques in order to analyse 
long-term effects. This, in turn, requires increasing cooperation of experts 
from different fields of science such as HTA, statistics, data management, 
modelling & simulation as well as visualisation. A common understanding 
on contents, methodology and terminology needs to be developed. In Aus-
tria, such a common understanding has hardly been elaborated in a system-
atic way so far.  
It is the main aim of the Innovative Framework for Evidence-based Deci-
sionmaking in Healthcare/IFEDH project to support evidence based deci-
sion making in health care by a service tool which helps profiting from exist-
ing potentials in HTA, modelling, simulation, statistics and data analysis. 
Therefore common standards will be defined in order to facilitate coopera-
tion and interdisciplinary work. Along three practical examples the tool will 
be tested regarding its applicability. 
This report addresses work package 1.2 that focuses on quality standards of 
HTA in general and on the evaluation of vaccination programmes in par-
ticular. It aims to answer the following research questions: 
 
What are general basic principles of standardised working in HTA? 
Which standards exist in order to assess data validity for HTA? 
Which standards exist in health economic research within HTA? 
Which standards exist in modelling within HTA? 
Which standards explicitly refer to evaluating vaccination programmes? 
Which are the limitations of HTA?  
 
high turnover in 
Austrian health system 
calls for interdisciplinary 
expert cooperation in 
evidence-based decision 
making 
service tool for 
evidence-based decision 
making in healthcare 
research questions 
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2 Methods 
2.1 Literature search 
Hand search was made for international manuals for HTA in German and 
English language. Methodological manuals and websites of leading interna-
tional institutions were screened. Beyond that, an international call via the 
International Network of Agencies for Health Technology Assess-
ment/INAHTA was launched. This network encompasses 46 institutions in 
24 countries. Within six weeks 12 institutions replied of which three were 
not able to deliver any material. The manuals and papers of two institutions 
were exclusively available in other languages than German or English and 
therefore could not be included. The seven remaining answers contained 
own papers of the institutions and links to other sources of information. 
Apart from institutions answering to the call, websites of all INAHTA coun-
tries were scanned.  
Additionally, the databases of the Cochrane Collaboration and the Centre 
for Reviews and Dissemination/CRD were screened, following a simple 
search strategy. Together, both searches added up to 177 hits after dedupli-
cation. The search strategies are added in the appendix. 
2.2 Selection of literature and terms 
Throughout literature screening, several manuals and many other docu-
ments were identified. In order to decide which of them were the most rele-
vant the following inclusion criteria were defined: 
We included reports that cover 
 explicit standards of HTA 
 standards of health economic evaluations 
 standards of modelling  
 information on the evaluation of vaccination programmes 
Furthermore, we limited the documents to those from institutions that have 
demonstrated an HTA tradition and that are accepted among the HTA com-
munity. In addition to these institutions there are several edited books and 
articles dealing with the topic of standardised procedures in HTA, mainly 
from authors who work in institutions cited above and/or contribute in net-
works such as INAHTA, the European Network for Health Technology As-
sessment/ EUnetHTA or the International Society of Pharmacoeconomic 
and Outcome Research/ ISPOR. These documents were not explicitly con-
sidered in our overview. 
We did not search for methodological papers in the field of modelling or 
health economic evaluation either, but only on those HTA-manuals which 
include the standards of these topics within HTA. 
 
 
hand search and 
international call 
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small systematic search 
in Cochrane database 
and CRD 
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no methodological 
papers but HTA-
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Selected core documents were summarised in tables according to the follow-
ing criteria 
 main characteristics of methodologies in international HTA institu-
tions including structure and content of different types of HTA re-
ports and the core methodological approaches stated 
 modelling approaches provided by the documents 
 approaches for modelling vaccination programmes 
 
For the field of vaccination the scope of search was widened. For reason of 
extremely limited evidence in classical HTA manuals we included guide-
lines or recommendations published by international institutions (e.g. 
WHO) or documents that were commissioned by public institutions (e.g. 
Gemeinsamer Bundesausschuss in Germany). 
 
 
method to summarise 
the literature 
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3 Results 
The following list (table 3-1) shows institutions which published methodo-
logical work on HTA in general or in particular on health economic evalua-
tions, modelling or standardised vaccination programme evaluation: 
Table 3-1: List of HTA institutions included 
Institution  Country 
INAHTA - International Network of Agencies for Health 
Technology Assessment 
 
International 
EUnetHTA - European Network for Health Technology 
Assessment 
 
EU 
ISPOR - International Society of Pharmacoeconomic 
and Outcome Research 
 
International 
WHO – World Health Organisation  International 
Austrian Ministry of Health/GO¨G – Gesundheit 
O¨sterreich GmbH 
 
Austria 
LBI-HTA – Ludwig Boltzmann Institut fu¨r HTA  Austria 
DAHTA@DIMDI - German Agency for HTA at the Ger-
man Institute for Medical Documentation and Informa-
tion 
 
Germany 
IQWiG – Institute for Quality and Efficiency in Health-
care 
 
Germany 
KCE - Belgian Federal Health Care Knowledge Centre  Belgium 
DACEHTA - Danish Centre for Health Technology As-
sessment 
 
Denmark 
INFAMED - National Authority of Medicines and 
Health Products 
 
Portugal 
HIQA - Health Information and Quality Authority  Ireland 
NETSCC, HTA - NIHR Coordinating Centre for Health 
Technology Assessment 
 
United Kingdom
CADTH – Canadian Agency for Drugs and Technology in 
Health 
 
Canada 
CDC – Centers for Disease Control and Prevention  USA 
MSAC - Medical Services Advisory Committee of the 
Department for Health and Ageing - DHA 
 
Australia 
PBAC – Pharmaceutical Benefits Advisory Committee of 
the Department for Health and Ageing - DHA 
 
Australia 
 
list of HTA-institutions 
included 
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3.1 General principles of standardised work 
in HTA 
In order to provide an overview of standards in HTA, table 3-4 lists the main 
characteristics of HTA methodologies of the relevant documents at a glance. 
The core characteristics and similarities as well as differences between dif-
ferent manuals are described in the following chapters. 
3.1.1 General principles of scientific work and 
particular charakteristics of HTA 
Like in any other scientific field general principles of scientific work such as 
traceability in methods and transparency in data gathering and presenta-
tion, correct citation and logic consistency are core requirements in HTA. 
HTA is a method of providing systematic, transparent, unbiased and scien-
tifically based policy advice in health care. Since HTA tries to state a 
counter-movement to the kind of policy which is based on so called “emi-
nence-based medicine”, and therefore a lack of methodological transpar-
ency, the general principles of transparency and unbiased work play a key 
role in HTA-research.  
Additionally, the interdependence of different scientific sub-disciplines and 
the need of a clear distinction between critical scientific appraisal and a po-
litical decision are other reasons for the strong focus that is put on transpar-
ency in HTA.  
The immanent nature of HTA as a multidisciplinary approach implies a cer-
tain context-dependence. E.g. the choice of a type of an economic evaluation 
depends on the setting of financing and on the acceptance of specific theo-
ries in the national or regional context. The best known examples is the con-
cept of quality adjusted life years/ QALYs, a concept that expresses the 
benefit of an intervention which is based on a utilitarian theory of social 
value. This concept is a standard tool in many countries such as the United 
Kingdom, Australia or the Netherlands. Other countries such as Austria and 
Germany (see chapter 3.3) do not accept major theoretic implications of this 
approach for ethical or political reasons. Therefore they either modify it, or 
do not use it at all in standardised healthcare decision making. 
3.1.2 Different types of HTA products 
The main product in HTA is the classical HTA report. It is based on a sys-
tematic literature search and, besides a clinical and economic assessment of 
the health technology under investigation may contain assessments on sev-
eral other fields such as organisational, social or legal aspects related to the 
technology. A classical HTA-report usually finishes with a discussion of the 
results and limitations and (in some countries) with a recommendation for 
decision makers. 
overview of HTA 
characteristics in table 
general principles of 
good scientific practice 
combined with EbM and 
interdisciplinarity 
special need of 
transparency 
dependency on regional 
and cultural contexts 
 (full) HTA reports, 
based on clinical and 
cost-effectiveness + 
further issues 
Results 
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A core methodological document in that context has been developed during 
the EUnetHTA project. EUnetHTA is an EU-based cooperative initiative 
which aims to define and to develop standards and tools for HTA users and 
producers. The so called “EUnetHTA Core Model” [1] which has been de-
veloped until December 2008 gives a general understanding of contents and 
structures of HTA reports by defining “issues”, subordinated to “topics” 
which again are parts of “domains”. It is providing one of the most exhaus-
tive and structured definitions of HTA.  
The domains covered by the core model are: the current use of technology, 
description of technical characteristics, safety, effectiveness, costs, economic 
evaluation, ethical aspects, organisational aspects, social aspects and legal 
aspects. One example for a safety topic would be the identification of harms. 
This is treated in issues in the form of questions such as “What is the scope 
of the harms to be assessed?”, or “What types of harms are of interest for the 
assessment?”  
The other institutions stated in table 3-1 are basically focusing on similar 
domains such as clinical effectiveness, safety, economic analysis, as well as 
ethical, organisational or legal aspects. Hence, the methods of HTA are 
highly compatible and do not differ very much between the countries. The 
contents of full HTA reports are similar (see: table 3-4, column 2). 
Nevertheless there are some differences in the approach of doing HTA be-
tween countries. Some countries are investing important parts of public re-
sources in primary data collection by commissioning randomised controlled 
clinical trials. Simultaneously economic data may be collected for doing an 
economic evaluation alongside a clinical trial. In the majority of manuals, 
however, secondary clinical and economic data are gathered and may be 
combined for doing economic evaluations. The former such as the United 
Kingdom, the United States of America or Australia usually do not see a 
clinical added value as a precondition for a health economic evaluation (see 
chapter 3.3) while others (e.g. IQWIG) do economic evaluations only if clini-
cal benefits of a technology have been demonstrated .  
A second often produced report within HTA is the so called “rapid assess-
ment”. It is a way of covering the main aspects of an HTA report with lim-
ited resources. Clinical and (sometimes) economic assessments are still the 
dominant, but not the only parts treated in such a format. Different institu-
tions define rapid assessments according to their needs and priorities. Some 
HTA institutes such as those in Germany or Austria have defined an explicit 
framework for rapid assessments. Others such as the DACEHTA, the KCE 
or EUnetHTA only define so called “full HTAs” and their different areas’ 
special relevance and context-dependency. According to this description, in 
a rapid assessment, some of these domains have to be treated in more detail 
than others. 
3.2 Clinical assessment 
The assessment on clinical effectiveness and safety is the main item of an 
HTA. The methodology relies strongly on principles of evidence-based 
medicine (EbM) and clinical epidemiology. Since the manuals generally rely 
on international standards of EbM, they are quite coherent with respect to 
clinical assessment, compared to other domains of the assessment. 
 “Core Model” by 
EUnetHTA cooperation, 
defining full HTA 
reports via domains, 
topics and issues 
methods in HTA highly 
compatible 
different traditions 
especially in economic 
evaluations 
rapid assessments – 
brief version 
clinical effectiveness 
and safety is core item 
consensus on EbM 
standards 
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In order to avoid any possible kind of systematic error (bias), in clinical epi-
demiology (double-blinded) RCTs are the preferred study design to evaluate 
the clinical benefit of a technology. Usually this refers to the ‘efficacy’ of a 
technology. Depending on the nature of the technology, the current state of 
art and the availability of evidence, other studies (e.g. pragmatic CTs, cohort 
studies or case-control studies) can also be used to assess clinical questions. 
This is particularly the case for evaluating adverse events but may also be 
relevant for other questions such as effectiveness (performance of a technol-
ogy under real-life conditions). 
3.2.1 The research question 
The main framework in any clinical assessment in the manuals analysed is 
the “PICO”-question. This methodology is the standard method in clinical 
epidemiology and therefore as well used in many HTA manuals,  such as the 
GÖG, KCE, EUnetHTA, CADTH or IQWIG [1-5]. PICO is a standardised 
way of designing the research question, dealing with the following sub-
questions: 
 Population / patients with the disease of interest 
 Intervention(s), i.e. the technology under assessment 
 Comparison(s), that should serve as reference 
 Outcomes which encompass the endpoints for assessing effectiveness 
and safety 
3.2.2 Literature search 
Once the research question is formulated, relevant literature needs to be 
searched. There is an important distinction between a systematic literature 
search and a so called “handsearch”. Following an explicit search strategy 
which defines the type of studies to search for a systematic literature search 
is conducted in relevant databases. Articles are then selected according to 
pre-defined inclusion- and exclusion-criteria [4]. Manuals recommend that 
literature selection should be done by two independent researchers first after 
abstract and second after full text lecture.  
All manuals point out the importance to do the selection in a transparent 
way and to publish the documentation of literature selection. One common 
tool of documentation is the PRISMA framework. This framework is a flow 
chart that pictures the process of literature search and selection. It shows 
which papers were identified, ordered and finally in- or excluded for what 
reason and at what stage of the selection process. Together with the search 
strategies of the databases screened the PRISMA table gives the main infor-
mation of the search protocol [6]. For an example see Warmuth, Johansson 
2010 [7] and table 7.3-1 in the appendix. 
A non systematic literature search, also known as handsearch, is generally 
seen as a way of second choice or as an add-on. Still there might be good rea-
sons for doing a handsearch, such as the lack of a certain type of literature in 
databases (e.g. grey literature, web-site information,…) or the need of in-
cluding very recent information which has not found the way through jour-
nal review procedures. In such cases a quality assessment is especially rele-
vant. 
RCTs as preferred source 
of evidence, hierarchy of 
evidence 
PICO - question 
systematic literature 
search sometimes 
completed by 
handsearch 
transparency in 
literature search and 
selection by PRISMA 
table 
search for grey 
literature sometimes 
more efficient by 
handsearch 
Results 
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Some institutions e.g. the National Institute for Health and Clinical Excel-
lence/ NICE have included other ways of literature search and information 
gathering into their assessment procedures. Within stakeholder involvement 
procedures patient representatives, producers or other commentators are 
systematically invited to add information to the assessment on the technol-
ogy or other relevant contextual issues at well specified points in time [8, 9]. 
3.2.3 Literature assessment 
For a clinical research question literature assessment includes a judgement 
on the following questions [3]: 
 Is the article relevant to the subject? 
 Are the article’s results valid? 
 Are the article’s results important for answering the question? 
 
Once a study is identified as relevant data have to be extracted into an evi-
dence table (see chapter 3.2.5). 
3.2.4 Data quality assessment 
Internal validity is the precondition of a study to be included in the assess-
ment. A good judgement on internal validity requires identification of po-
tential systematic errors. The main limitations for the quality of an RCT are: 
 Incorrect randomisation 
 Incorrect allocation concealment 
 Clinical dissimilarities between the groups 
 Lack of power 
 Incorrect blinding 
 High drop-out rate 
 Lack of intention-to-treat analysis 
 
Types of potential bias can differ with different types of studies. Most com-
mon forms are confounding, selection bias and information bias. There is 
nothing such as a complete list of biases for one or a group of study types. 
Even though there is not complete consensus whether validity of studies 
should be assessed with checklists, they still exist and are widely used. Some 
manuals such as the Austrian [10] or the manual by KCE [3] add them as an 
appendix to their manuals. Widely used checklists are the Cochrane check-
list [11] for assessing RCTs or the QUADAS [12] tool for quality assessment 
of diagnostic studies. DIMDI has recently also provided checklists on 
“methodological quality of primary and secondary studies in HTA reports” 
[13]. Once a study has been checked and included with respect to its internal 
validity, data on effectiveness and safety can be extracted and assessed. The 
results from the quality assessment of the studies are either used to include 
or exclude studies or they are incorporated into the overall rating of the evi-
dence as it is for example the case in the GRADE-methodology. 
 
stakeholder 
involvement 
primary selection 
criteria 
internal validity of data 
identifying and avoiding 
systematic errors such 
as confounding, 
selection bias, 
information bias 
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3.2.5 Data extraction 
Data extraction should be executed by one author and double-checked by an 
independent person. 
A clinical data extraction should contain the following issues [4]: 
 General information on the study (author, year, country/health sys-
tem, aim of the study, details of study funding) 
 Specific Information on the study (design, duration, no. of patients, 
inclusion criteria of the population, characteristics of the population, 
intervention/exposition, outcomes parameters) 
 Results (relevant outcomes, effect size, confidence interval and p-
value including not significant results) 
 Internal validity (quality) 
 Comments 
For an example of data extraction see [14]. 
3.2.6 Analysis and critical appraisal 
The actual assessment and the critical appraisal of literature can be executed 
in different ways. These ways particularly differ in the extent of their quan-
titative approach.  
A qualitative way of analysing clinical evidence is the methodology of the 
GRADE-working group [15]. It is based on evidence tables that summarize 
the effect sizes of different studies in a qualitative manner including a tool 
to grade the evidence according to its quality. GRADE is explicitly recom-
mended by the Austrian, Danish, Belgian and German manuals. 
The prototype of quantitative analysis is to conduct a meta-analysis. In a 
meta-analysis the statistical data of several studies on the same topic are 
combined and analysed as if it was data from one study. It is evident that 
such a type of analysis can only be conducted if it is for sure that there is no 
contextual interference which has a systematic influence on the overall re-
sults. In order to avoid heterogeneity, studies that are similar in setting and 
parameters addressed are to be included in a meta-analysis. The Cochrane 
Collaboration offers a free software called “Review Manager” to execute 
meta-analyses which is also used by the Belgian KCE and other institutions. 
Apart from the Cochrane Collaboration, meta-analyses are treated in the 
Austrian manual, by IQWIG, DACEHTA, KCE, NICE, CADTH and HIQA. 
In all these manuals meta-analyses are seen as the ideal way to assess exist-
ing clinical evidence, but as a dangerous method if data are not well assessed 
in order to be sure that they are standardised and comparable. 
Not least the clinical question can be approached by a decision analytical 
model where several data sources are combined in a mathematical model in 
order to analyse benefits and risks of alternative interventions. Methodologi-
cal standards for modelling within HTA are described in chapter 3.5. 
 
 
clinical data extraction 
procedure 
different grade of 
quantitative approach in 
appraisals 
GRADE-tool for 
qualitative evidence 
synthesis 
meta-analysis  for 
quantitative evidence 
synthesis 
Some manuals describe 
details of meta-analyses  
modelling approach for 
evidence synthesis  
Results 
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3.3 Economic analysis 
The relevance of economic analysis in an HTA varies considerably between 
different institutions and countries. In general it is common understanding 
that economic analysis is seen as a part of HTA. Still some countries such as 
the United Kingdom, Australia or Canada emphasise its relevance a lot 
more than others. Additionally, some manuals focus on how to conduct an 
economic analysis while others restrict the economic analysis to a summary 
of secondary literature and describe how to include this information into an 
HTA-report. All in all, the methodology of economic evaluation is – with 
some exceptions as described down below - highly standardised and well 
known in the international community of HTA. 
3.3.1 Economic evaluation 
The most widely used types of economic analysis are health economic 
evaluations (see table 3-2). Health economic evaluations are generally de-
fined as studies comparing two or more treatment options in terms of their 
costs (in monetary terms) and their benefits. There are four standard types 
of economic evaluations which are characterised by the way of expressing 
benefits of an intervention [16, 17]: 
Table 3-2: Types of health economic evaluations 
Type of analysis Costs measured in Benefit measured in 
Cost-minimisation 
analysis / CMA 
monetary units equal benefits  
assumption 
Cost-effectiveness 
analysis / CEA 
monetary units natural units  
(e.g. live years gained) 
Cost-utility analysis / 
CUA 
monetary units utilities transferred 
into generic units 
(e.g. QALY) 
Cost-benefit analysis / 
CBA 
monetary units monetary units 
 
In a CMA it is assumed that both therapies have exactly the same clinical ef-
fects. Obviously this is true very rarely and therefore is hardly used, but can 
still be a helpful tool. A CBA is limited by the strong constraint of monetary 
validation of every single medical benefit or harm. Therefore usually a will-
ingness-to-pay approach as considered by CADTH is chosen [2]. CEA and 
CUA are the most commonly used evaluations. The CEA measures the bene-
fit of an intervention in natural units in order to create a cost-effectiveness 
ratio e.g. cost per life years gained / LYG. The CUA uses generic units such 
as the quality adjusted life year / QALY which is a combined index of qual-
ity of life and mortality. 
varying relevance of 
economic analysis  
standard: health 
economic evaluations 
compares different 
treatment options in  
terms  of benefits and 
costs => 4 types 
CMA, CEA, CUA and 
CBA differ in benefit 
measurement 
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The manuals differ with respect to the evaluation type recommended. Most 
countries recommend cost-utility analysis as one option. Some such as Aus-
tralia [17] or the United Kingdom [8] explicitly focus on this evaluation 
type. On the contrary, Germany rejects cost-utility analyses in public deci-
sion-making and follows a different route: In the IQWIG manual, compari-
son between alternative types of treatment is restricted to technologies 
within the same indication (e.g. medication for elevated blood pressure) 
while technologies across indications (e.g. cancer therapy versus therapies in 
cardio vascular diseases) must not be evaluated economically. Within an in-
dication, new technologies are assessed according to their ratio between in-
cremental costs and their additional benefit. Assuming that the most cost-
effective technology is used as long a possible, followed by a more cost-
effective technology, a new technology has to be at least more efficient than 
any other technology in use. This is expressed by the so called “efficiency-
frontier”. 
Manuals additionally differ in methodological details. Some institutions do 
exclude any indirect costs [18]. Others consider indirect cost as an essential 
source of information which closes the gap between a theoretic pricing 
framework and real life. Main practical steps in the determination of costs 
are [18]: 
 Identification of resource consumption 
 Entry of quantities of resource consumption 
 Valuation of quantities 
 Calculation of total costs of treatment alternatives 
 
The description of cost-analysis in the manuals is closely related to the per-
spective from which economic evaluations are to be conducted. The Austra-
lian and the Irish manuals [17, 19, 20] e.g. are examples for a public payers’ 
perspective. Other manuals such as the Danish or the Belgian [3, 16] do not 
explicitly specify which perspective should be chosen for an evaluation to be 
useful.  
Another essential element of economic calculations is the discounting-
process. This weighting has to be executed in order to validate all invest-
ments according to one and the same point in time. The longer the time ho-
rizon of a calculation the more important this aspect becomes. Some manu-
als recommend a discounting rate of 3%. Others do not give any specifica-
tion on this topic. Since treatments have different harms end benefits in 
short and long term, the choice of the time horizon can also have an impact 
on the clinical benefit of a treatment. Therefore it can influence the result of 
a health economic evaluation in more than one way. Manuals such as the 
HIQA or the CADTH manual primarily recommend being transparent 
about the choices of perspective and timing horizon. CADTH especially rec-
ommends choosing a time horizon that is clinically relevant. Depending on 
causal relationships CADTH considers the possibility of multiple modelling 
for different time horizons. 
It is not always evident which clinical outcome is the best to choose in an 
economic evaluation. As in clinical evaluation, the majority of manuals rec-
ommend to choose patient relevant indicators. Therefore in CEAs one fre-
quent ratio is the cost per live years gained, and in CUAs the cost per QALY. 
The predominant outcome of CEAs and CUAs is the incremental cost-
effectiveness ratio / ICER.  It expresses the ratio of change in costs and out-
Australia or UK different 
approach than Germany 
 
IQWIG: economic 
comparison only for 
treatments in the same 
field of indication;  
“efficiency frontier”  
differences in cost 
analysis 
different perspectives 
ask for different cost 
analyses 
realistic time horizon 
relevant for clinical and 
economic assessment 
patient relevant 
outcomes recommended 
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comes of the compared treatments. Several manuals from Canada, Ireland, 
United Kingdom, Portugal or Australia [2, 19-22] formulate guidelines to 
use ICERs as outcome measures.  
To validate results most manuals recommend performing sensitivity analy-
ses. The Canadian model gives the most detailed guidelines on how to deal 
with uncertainty and variability (table 3-3). Depending on the type of uncer-
tainty or variability there are different approaches recommended [2]:  
Table 3-3: Handling variability and uncertainty 
Category Type of Variability or Uncertainty Recommended Approach 
Variability Differences in clinical practice pat-
terns between geographic areas or 
settings 
Sensitivity analysis 
 Variability in patient population (pa-
tient heterogeneity) 
Stratified analysis 
Model-based 
uncertainty 
Model uncertainty 
 analytical methods 
 model structure 
 assumptions 
 data sources 
DSA using alternative assump-
tions, one-way, multi-way, 
threshold, or extremes analysis; 
and model validation methods 
 Parameter uncertainty DSA using one-way, multi-way, 
threshold, or extremes analysis; 
PSA using Monte Carlo simula-
tion is encouraged 
 
Such a framework can probably not be seen as the international standard 
every HTA institution is following, but since CADTH is a highly prestigious 
institution and covers leading positions in INAHTA and ISPOR it can be 
considered as one of the main methodological guidelines existing in the field 
of HTA. 
3.3.2 Other types of economic analysis 
Apart from health economic evaluations there are business-economic analy-
ses and budget-economic analyses. They play a minor role in the manuals 
and are primarily described in the Danish and German manuals [16, 18]. 
Business-economic analyses are mainly performed to support service pro-
viders such as hospitals in their planning. Therefore they also deal with the 
questions of financing, maintaining, operating, and gaining savings from a 
technology.  
Budget-economic analyses are a support tool for health care financing insti-
tutions such as insurance companies or public authorities. They are used to 
assess the impacts of investment for a technology/programme on long-term 
costs and potential cost-containment. Therefore it is a support in priority-
setting [18]. 
CADTH guidelines on 
uncertainty 
others: business 
economic analyses… 
… and budget-economic 
analyses 
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3.3.3 Secondary data of economic analyses within 
HTAs 
Often it is not possible to execute primary economic evaluation for every 
HTA. The Canadian agency CADTH [2] and the Austrian HTA manual [23] 
give a methodological guideline for reviews of economic studies. The re-
search process of conducting a review of economic evidence is similar to re-
viewing clinical evidence in that transparency in literature search, definition 
of selection criteria and selection method, data extraction, the strategy of 
data assessment of the studies (e.g. use of checklists [3] of quality assessment 
scales), and information on the data analysis methods are described.  
However, the research question itself needs to be defined clearly in advance 
in order to benefit from a review on economic evidence. Differences between 
health care systems, in terms of service provision as well as in terms of fund-
ing, have major impacts on the generalisability of economic parts of HTAs. 
Hence, the question whether some technology is cost-effective compared to 
another can hardly be answered sensibly via a review of economic evalua-
tions. Yet, a review can be useful in other circumstances (e.g. if information 
is needed for conducting ones own study). 
Just like clinical data, economic data in a review has to be assessed in terms 
of validity before it can be included in any analysis. Therefore checklists 
have been developed as well. Two important examples are the one of 
Drummond and Jefferson and the one of Siebert et al. [24, 25]. 
For summarising the economic evidence several approaches have been rec-
ommended [10], however, they are much less standardised than for clinical 
evidence. Not least, economic analyses can be supported by decision analytic 
modelling which will be described in chapter 3.5. 
3.4 Ethical, social and legal issues within an 
HTA report 
Besides clinical and economic analysis there are several issues which are 
generally seen as important parts of HTA methodology. Still these issues are 
not approached in the same comparably unanimous way as the two main ar-
eas. Ethical considerations are a good example for a field that is commonly 
mentioned by every HTA manual. It is treated in detail by some institutions 
such as the EUnetHTA, DACEHTA, or within the Austrian manual but al-
most ignored by some others such as the manual by NICE or by the Austra-
lian PBAC. Even considering that some manuals such as those of CADTH 
or KCE are much shorter than these, they still contain more information 
and guidance on how to deal with ethical considerations.  
In terms of ethics, most manuals mention the discussion on the concept of 
Quality Adjusted Life Years. This concept is sometimes criticised for dis-
criminating the elderly. Another ethical discussion addresses the issue if pa-
tient relevance of clinical outcomes is most important or if individual satis-
faction should be considered as well.  
some manuals include 
methods on review of 
economic evidence 
sensible research 
question required 
checklists for data 
assessment available 
summarising evidence 
less standardised 
other aspects than 
clinical and cost-
effectiveness relevant 
 
mainly ethical, 
organisational, social 
and legal issues 
QALY questioned from 
ethical point of view 
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In some manuals [1, 2, 10, 22] the discussion of efficiency versus equity and 
the utilitarian approach of health economic evaluation is at the core of the 
ethical issues covered. The Anglo-Saxon approach of NICE and PBAC 
seems very utilitarian, whereas European continental countries such as Aus-
tria or Germany seem to be more critical. The Belgian paper is rather brief 
and does not break down concepts on a very detailed level. Still it contains a 
relevant part on the patient and the societal level of patient and ethical is-
sues and indicates different scientific approaches to analyse such aspects 
within an HTA. 
Ethical aspects do also occur in the clinical analysis and even earlier in the 
setup of a study design. To a certain extent this field is covered by legal 
rules, regimentations and procedures. Apart from ethical aspects the field of 
legal aspects mainly influences the important question on applicability of 
technologies, implementation of service provision or transferability of tech-
nologies from one regional or national context to another. 
The terminus of “psychosocial considerations” is only used by the 
EUnetHTA, the Canadian and the Austrian manual. The Canadian agency 
defines it as “intangible” factors for those affected by a technology. The Aus-
trian manual enhances the factor of the individuals’ perception of a technol-
ogy and its influence on an efficient implementation. This meets the consid-
eration of different perspectives, and in the end the involvement of stake-
holders which is rather represented in the Anglo-Saxon culture. 
The scope of topics existing apart from clinical and cost effectiveness seems 
to be beyond important dispute, but the extent to which institutions are 
really including these topics in their HTA manuals and finally in their 
HTAs varies considerably. 
 
utilitarism in Anglo-
Saxon countries 
brief Belgian manual 
includes patient and 
societal level 
 
ethical aspects also meet 
legal issues; 
legal issues strongly 
connected with 
transferability 
psychosocial 
considerations rare, 
sometimes  dealt with 
by stakeholder 
involvement 
consensus on topics but 
not on execution 
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Table 3-4: Main characteristics of methodologies in international HTA institutions 
STRUCTURE AND CONTENTS OF REPORTS METHODS Country, agency 
HTA reports Rapid assessments Clinical assessment Economic analysis Other aspects 
EU: 
EUnetHTA [1] 
9 Core domains:  
1. current use of technology 
2. description of technical 
characteristics 
3. safety 
4. effectiveness 
5. costs, economic evaluation 
6. ethical aspects 
7. organisational aspects 
8. social aspects 
9. legal aspects  
The extent of an HTA can considerably 
vary as long as it follows the 
methodology and the interest of the 
topic; 
Evidence-based 
approach; Good 
epidemiological 
practice /GEP1 [26]; 
Ideally but not 
compulsory based on 
RCTs; focus on 
effectiveness and 
patient relevant 
questions such as side 
effects or ethical 
considerations; 
Target population, 
intervention, 
comparators, 
outcomes, time frame 
and perspective are 
essential aspects of a 
health economic 
evaluation; 
Detailed framework 
on ethical, 
organisational, 
societal and legal 
aspects as well as on 
the context of the 
technology assessed; 
Austria: 
LBI-HTA, GO¨G [4, 10] 
Methodology, literature search, 
literature selection, data assessment, 
data extraction, analysis and 
synthesis; focus on clinical 
effectiveness and safety; 
Explicit framework for rapid 
assessments 
GEP; hierarchy of 
clinical study designs; 
internal and external 
validation of identified 
literature 
n.a. Framework for 
systematic analysis of 
socio-cultural 
implications including 
psychosocial, ethical, 
legal and 
organisational aspects; 
Germany: 
IQWIG [5, 18] 
Effectiveness, safety, economic 
analysis, patient relevance, patient 
information; 
Explicit framework for rapid 
assessments 
GEP; hierarchy of 
clinical study designs; 
internal and external 
validation of identified 
literature 
Health economic 
evaluation and 
modelling if clinical 
benefit is proven; 
efficiency-frontier 
approach 
Implicit expression of 
legal and 
organisational aspects 
through definition of 
contexts of clinical and 
economic analyses;  
Germany:  
DAHTA@DIMDI [27] 
Societal background, medical aspects, 
health economic aspects, ethical and 
social aspects, legal aspects; 
Explicit framework for rapid 
assessments 
GEP; hierarchy of 
clinical study designs; 
internal and external 
validation of identified 
literature 
International evidence 
with regard on 
applicability; 
General guidance on 
how to present ethical 
, social and legal 
aspects; 
                                                             
1 “Good Epidemiological Practice” / GEP [4] is defined by the International Epidemiologic Association as in the IEA GUIDELINES FOR PROPER CONDUCT IN EPIDEMIOLOGIC RESEARCH. 
These Guidelines include procedural rules for good research behaviour as well as ethical principals, or the role of ethics committees. 
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STRUCTURE AND CONTENTS OF REPORTS METHODS Country, agency 
HTA reports Rapid assessments Clinical assessment Economic analysis Other aspects 
Belgium: 
KCE [28] 
Clinical effectiveness, cost-
effectiveness, patient issues, 
organisational issues; 
n.a. GEP; hierarchy of 
clinical study designs; 
internal and external 
validation of identified 
literature 
Cost-effectiveness 
analyses and cost-
benefit analyses and 
their quality control; 
Guidelines on ethical 
and patient issues on 
individual and societal 
level 
Denmark: 
DACEHTA [16] 
Literature search and assessment, 
data, technology and patient issues, 
organisation, economic evaluation, 
synthesis and utilization, quality 
assurance and presentation; 
Documentation of different types of 
HTA products 
GEP; hierarchy of 
clinical study designs; 
internal and external 
validation of identified 
literature 
Health economic 
evaluations including 
modelling approaches 
as well as other types 
of health economic 
studies; 
Exhaustive description 
of ethical 
considerations, patient 
aspects, organisational 
aspects and the 
question of how to use 
an HTA 
Portugal: 
INFARMED [21] 
PICO (see 3.2.1), time horizon, 
analysis techniques, identifying costs, 
measuring and valuing costs, 
measuring consequences,. total and 
incremental analysis, discount rate, 
uncertainty, ethical aspects; 
n.a. n.a. Guidelines for 
economic drug 
evaluation studies 
n.a. 
Ireland: 
HIQA [19] 
Evaluation types, perspectives of 
costs and outcomes, choice of 
comparator, synthesis of 
effectiveness, outcome 
measurement, discounting, 
sensitivity analysis, equity rating; 
n.a. n.a. Detailed structured 
guidelines on 
economic evaluations; 
Equity considerations 
referring to the QALY 
concept (see 3.3)  
UK:  
NETSCC [8, 9, 22] 
Clinical effectiveness is not a 
precondition for the economic 
assessment of a technology;  strong 
focus on clinical and cost 
effectiveness, scoping and 
stakeholder involvement; 
n.a. GEP; hierarchy of 
clinical study designs; 
internal and external 
validation of identified 
literature 
Cost-effectiveness 
analyses and cost-
utility analyses as a 
precondition for 
reimbursement 
decisions, economic 
analysis alongside 
randomised controlled 
clinical trials; 
Very limited and 
general statement on 
the usefulness of 
ethical considerations 
and on feasibility, 
impact, equity and 
equality; 
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STRUCTURE AND CONTENTS OF REPORTS METHODS Country, agency 
HTA reports Rapid assessments Clinical assessment Economic analysis Other aspects 
Canada: 
CADTH [2] 
PICO (see 3.2.1), perspective, 
effectiveness, time horizon, 
modelling, valuing outcomes, 
resource use and costs, discounting, 
variability and uncertainty, equity, 
generalisability; 
n.a. GEP; hierarchy of 
clinical study designs; 
internal and external 
validation of identified 
literature 
General guidelines, 
resource identification 
guidelines, resource 
measurement 
guidelines and 
resource valuation 
guidelines; 
“Health services 
impact” considerations 
including population, 
budget, 
implementation, laws, 
psychosocial and 
ethical issues; 
Australia: 
PBAC, MSAC [17] 
Description of intervention, 
evaluation for indication, economic 
evaluation; 
n.a. GEP; hierarchy of 
clinical study designs; 
internal and external 
validation of identified 
literature 
Detailed guidelines for 
preparing health 
economic evaluations 
and analyses; 
Focus on legal and 
administrative aspects, 
hardly any ethical 
considerations; 
n.a.: not available. Such fields express the lack of an explicit methodological paper in this field. Institutions may use standards of institutions from other countries or expert groups. 
 
Results 
LBI-HTA | 2011 23 
3.5 Modelling standards in HTA manuals 
In order to deal with a lack of data and to get an idea of how an actual situa-
tion might change in the future, certain circumstances given, mathematic 
modelling is in many fields of HTA a practical approach. In HTA, model-
ling can be used in the clinical as well as in the economic part of the assess-
ment. Briggs et al. describe the necessity of decision modelling for health 
economic evaluations with “…the need to synthesize all relevant evidence 
and to compare all options over an appropriate time horizon” [29].  
Most of the national agencies do not provide detailed methodological guid-
ance on modelling in HTA (see table 3-5). Some of them provide basic in-
formation. Important capacity lies in individual knowledge, academia and 
the network of the International Society for Pharmacoeconomic and Out-
come Research/ ISPOR.  Some agencies have started over the years to up-
date their guidelines with remarks on modelling, such as CADTH.  
The most common types of models in HTA mentioned in the manuals are 
decision tree models, Markov models, cohort- or individual simulation, as 
well as more recently discrete event simulation/ DES, agent-based simula-
tion and transmission models [30]. The main steps in creating a model are 
described by the IQWIG as follows: 
 Precise definition of research question 
 Diagram of influence factors 
 Model concept 
 Systematic search for data available, if needed primary data survey 
 Definition of functional relations in the model 
 Choice of model type in order to structure the model 
 Implementation and programming of the model 
 Validation of the model as well as sensitivity analyses 
 Writing a report including a transparent description of the model and 
a critical discussion of assumptions and limitations 
 
This punctuation can already be seen as a basic guideline for “how to do 
modelling in HTA”. On an international level, standards are discussed and 
developed by members of the International Society of Pharmacoeconomics 
and Outcome Research/ ISPOR. Another important paper has been pub-
lished by Philips et al., including a checklist for good practice in decision-
analytic modelling in HTA [31]. Similarly, the Australian Pharmaceutical 
Benefits Advisory Committee/ PBAC claims a high level of transparency 
and documentation regarding the methods used in modelling [17]. It explic-
itly asks to present any details of the model such as decision trees, transition 
diagrams, or to answer if a Markov-model includes constant transition prob-
abilities or not, and if the ‘memorylessness’ assumption of the model is 
valid. Such requirements are not formulated in an explicit guideline on 
modelling, but they are part of the overall requirements a submission to the 
PBAC has to fulfil. 
 
 
modelling useful in 
cases of uncertainty 
main information in UK, 
Canada and ISPOR 
most common types of 
modelling in HTA 
guidance vs. checklist… 
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One of the most detailed general guideline for modelling in the manuals is 
provided by the CADTH-manual. Since 2006 it mentions the following con-
siderations which are supported by more detailed guidelines on each point [2]: 
 
Modelling considerations:  
 Follow good modelling practices when constructing the model used to 
conduct the evaluation. Analysts are encouraged to consult good mod-
elling practice guidelines as required. 
 Describe the model, including its scope, structure, and assumptions. 
Provide justification for assumptions and choices. 
 Use a model structure that is appropriate for addressing the study 
question. Build the model in such a way to permit updating of results 
as more data become available. 
 Explain and justify any causal relationships and extrapolation tech-
niques used in the model. Base the extrapolation of data on valid tech-
niques that reflect reasonable scientific evidence, and test through 
sensitivity analysis. 
 Formally validate the model, and state how this was done. 
 
Data considerations:  
 Systematically identify, collect, and assess the data used in the model 
 Report and identify all data sources. Explain and justify all parameter 
choices and assumptions. 
 Describe the quality (e.g., strength of evidence) of the data used in the 
model. Be explicit about data limitations and how they were dealt 
with. Try to quantify the impact of the limitations on the uncertainty 
of the evaluation results. 
 Gather the best available evidence on key model parameters for which 
the model results are most sensitive. Justify any failure to gather the 
best available evidence of such parameters. 
 Use caution when expert opinion is used to establish parameter val-
ues. Justify its use; and describe the source of the opinion, the method 
of elicitation, and the results of the exercise. Assess such estimates 
through a sensitivity analysis. 
 Use appropriate methods to analyze or combine data from different 
sources. Explain and justify the methods used, and report the results 
of the analysis. Report limitations in the methods or data used, and 
where feasible, test through a sensitivity analysis. 
 Incorporate data into the model using appropriate techniques, and 
explain the methods used. If data are incorporated as point estimates, 
use mean estimates of parameters in the base case. If estimates are in-
corporated as probability distributions, state and justify the form of 
the distributions. 
 
 
real “guidance’s” rare 
modelling 
considerations 
data considerations 
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Compared to this general guideline, Philips et al. [31] and the IQWIG [30] 
guidelines actually guide through the process of doing quality-assured mod-
elling in HTA by providing concrete checklists.  
Although the checklist by Philips et al. [31] is not an HTA manual itself it is 
mentioned in manuals and can be regarded as accepted standard. Grouped 
in “Structure”, “Data”, and “Consistency”, the authors define 16 elements of 
quality and areas of disagreement in previous guidelines. They provide rec-
ommendations on how to deal with disagreements and a framework for qual-
ity assessment of decision-analytic models in HTA. In this framework the 
dimensions of quality – e.g. the statement of the decision problem or the 
time horizon – is described by attributes of good practice and questions for 
critical appraisal – e.g. “Is there a clear statement of the decision problem?” 
or “Is the time horizon of the model sufficient to reflect all important differ-
ences between options?” Finally Philips et al. give an example for a quality 
assessment of a model, answering and commenting the assessment ques-
tions. 
Table 3-5: Modelling guidelines in international HTA institutions 
Country, agency Type of publication Type of information Quality criteria described 
EU: EUnetHTA [1] n.a. n.a. n.a. 
Austria: GO¨G, LBI-HTA [4, 10] Manual n.a. n.a. 
Germany: IQWIG [5, 18] working papers Main steps and requirements 
for good modelling practice 
in HTA 
Structured step-by-step approach; 
appropriateness of modelling 
tool;  
Germany: DAHTA@DIMDI 
[27] 
n.a. n.a. n.a. 
Belgium: KCE [28] n.a. n.a. n.a. 
Denmark: DACEHTA [16] HTA-textbook General information on the 
use of modelling in economic 
evaluations in HTA 
n.a. 
Portugal: INFARMED [21] Guidelines for economic 
drug evaluation studies 
General requirements of 
modelling documentation 
Transparency, discounting, 
documentation and discussion of 
limitations 
Ireland: HIQA [19] Guidelines for the 
Economic Evaluation of 
Health Technologies 
Short description of good 
modelling requirements 
Transparent documentation, 
validation, sensitivity analyses; 
UK: NETSCC [8, 9] Manual Short description of good 
modelling requirements 
Justification of structural 
assumptions, good 
documentation and justification 
of data inputs, avoiding selection 
of outlaying values, high 
transparency; 
Canada: CADTH [2] Guidelines for the 
economic evaluation of 
health technologies 
12 modelling principles and 
data considerations 
Following good practices, 
transparency and clearness, 
appropriateness, validation, 
documentation, critical appraisal; 
Australia: PBAC, MSAC [17] Submission guidelines to 
the PBAC 
Requirements of modelling 
documentation 
Transparency; 
Additional document on standards in modelling: 
Philips et al. [31] Scientific journal paper Good practice guidelines for 
decision analytic modelling in 
HTA 
Standards and assessment 
questions on structure, data and 
consistency 
Weinstein et al. [32] Scientific journal paper Good practice guidelines for 
decision analytic modelling in 
HTA 
Standards on model quality 
n.a.: not available 
NICE and CADTH less 
concrete than Philips or 
IQWIG 
Philips et al. define 
framework of 16 
elements of structure, 
data and consistency 
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3.6 Standards in evaluating vaccination 
programmes 
In searching for a case study topic for work package 8 in the IFEDH project, 
vaccination to prevent infectious diseases was identified as a relevant field of 
application. The dynamic of infection, the uncertainties linked to long-term 
effects of vaccination programs and the high number of vaccines that is ex-
pected to enter the market make this subject interesting for modelling. Con-
sequently, in WP1.2 we tried to identify manuals on standards of evaluating 
vaccination programmes and the role of modelling in this context. 
Unfortunately systematic documentation on evaluation and modelling stan-
dards in this field is very limited. Table 3-6 lists the four main sources of in-
formation which could be identified. Their main concern is an optimal as-
sessment of vaccination programmes. Still they are all approaching the topic 
from different angles. 
Table 3-6: Modelling in HTA for vaccination programmes 
Country, agency Type of author Type of document Focus 
Australia: 
PBAC 2008 [17] 
service provider 
submitting a 
technology to 
national authority 
guideline for 
submitting vaccination 
programme 
focus on clinical 
effectiveness, safety and 
cost-effectiveness; best 
information available; 
International: 
SMDM 2008 [33] 
academia journal article sensitivity analyses and 
uncertainty 
International: 
WHO [34] 
International public 
authority 
report standardization of economic 
evaluations of vaccine 
programmes 
Germany: 
IGES et al. 2010 [35] 
academia 
commissioned by 
public authority 
report focus on cost-effectiveness 
of vaccination programmes 
 
The PABAC document [17] provides a very general guideline on the type of 
information that is required when vaccines are submitted for reimbursement 
considerations. Concerning evaluation in general and modelling in particu-
lar it does not specify specific methodological requirements but rather out-
lines which type of information needs to be submitted:  
 Details of the proposed vaccine and its intended use 
Pharmacological class and action 
Indications and requested restrictions 
Treatment details 
Main comparator 
 Clinical evaluation for the main indication 
Assessing noninferiority between a vaccine combination product 
and its components 
Outcome measures 
Assessment of comparative harms 
infectious diseases 
potentially highly 
dynamic and uncertain 
=> need for modelling 
limited methodological 
standards on 
vaccination modelling 
Australia: information 
guideline for 
reimbursement 
application 
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 Translating the clinical evaluation to the listing requested for inclu-
sion in the economic evaluation2 
 Economic evaluation for the main indication 
Type of economic evaluation 
Population and circumstances of use reflected in the economic 
evaluation 
Structure and rationale of the economic evaluation 
Type of model 
Joint analysis 
Duration of a model 
Modelling of consequences 
Variables in the economic evaluation 
 Estimated extent of use and financial implications 
Estimated financial implications for the National Immunization 
Plan 
Estimated extent of use and cost of the proposed vaccine 
Estimated financial implications for government health budgets 
Estimated extent of use and cost of the proposed vaccine 
Estimated financial implications for government health budgets 
 
While details on methodological recommendations are missing, the docu-
ments identified address some general methodological issues, often related 
to the correct choice of models. 
For example the WHO created an algorithm called “WHO guide for stan-
dardization of economic evaluations of immunization programmes” [34]. 
This flow chart shows in which case what kind of model seems to be the 
most appropriate to calculate either a static or a dynamic model of a vacci-
nation initiative. 
 
 
                                                             
2 The results of trials might need to be  translated into a decision analysis appropriate 
for the intended clinical use of the proposed drug on the PBS (pharmaceutical 
benefits schedule)  in Australia 
in some documents: 
support in choice of 
modelling 
WHO algorithm to 
choose between static 
and dynamic model 
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Source: WHO guide for standardization of economic evaluations of immunization programmes 
(WHO 2008) [34] 
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As to the mathematical model of a vaccination programme the WHO [34] 
recommends to be: 
 Transparent in that the structure and implicit or explicit assumptions 
are all clearly described. 
 Static, if vaccination is unlikely to change the force of infection in 
susceptibles or as a means to make a conservative estimate when ex-
ternalities from herd-immunity cannot on the whole be adverse. 
 Dynamic, if vaccination is likely to change the force of infection in 
susceptibles, and a static model would not yield a conservative esti-
mate, or if the conservative estimate from a static model does not lead 
to an outcome which would be considered favourable by decision 
makers. 
 Stochastic if chance plays an important role in the transmission proc-
ess of the pathogen 
 Validated, in as many facets of validation (verification, calibration, 
face validity, predictive validity) as possible, but at least verified. 
 
Furthermore, Klein et al. [32] recommend keeping a model: 
 as simple as possible,  
 transparent, 
 dynamic (adaptable in case of a change in the rate of infection) 
 stochastic, and 
 validated in any possible dimension; 
 
Additionally, it has been acknowledged that vaccines are to be evaluated dif-
ferently than other health care technologies such as drugs. Klein et al. [35] 
show that vaccination programmes evaluations are different from other 
health technologies because they imply specific characteristics such as: 
 Positive externalities (lower infection risk of non-immunised peo-
ple)/herd-immunity 
 Uncertainty about duration of protection 
 Time gap between investment and potential benefit gained 
 Evaluation of dynamic cohorts 
 Transmission models for acute diseases 
 Markov models for chronic diseases 
 Big size of target population 
 
Herd immunity is seen as the most relevant factor for modelling vaccination 
programmes. It describes the phenomenon of non immunised people being 
protected in the group of immunised people and therefore is one major 
source of uncertainty.   
Another source of uncertainty is the problem of an uncertain time horizon, 
since for most new vaccines the period of immunisation protection cannot be 
defined exactly. Therefore modelling has to choose an approximate time ho-
rizon. A wrong choice – as mentioned in chapter 3.5 – mainly affects the 
clinical effect.  
WHO recommendations 
on mathematical models 
Klein et al. 
recommendations 
acknowledgment that 
vaccination implies 
specific characteristics 
different types of 
uncertainty: herd 
immunity, 
time horizon, 
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With respect to economic evaluations of vaccination, some attention has 
been paid to discounting of benefits and costs. Since benefits of vaccinations 
may be accrued in the far future a high discounting factor results in zero 
benefits after a certain time period. Consequently cost-effectiveness ratios 
become unfavourable. In that respect the WHO [34] gives the following rec-
ommendations: 
 Discount costs and effects initially using the rate in the country in 
question (for studies to inform local decision-makers) and then using 
a 3% discount rate (consistent with WHO-CHOICE and DCP2); 
 Conduct sensitivity analysis using discount rates of 0%, near-zero, 5% 
and 10% to reflect the (probably) higher real risk-free cost of capital 
in developing countries; 
 A non-constant (declining or ‘slow’) discounting procedure may be 
applied where the effects begin only long after the intervention, e.g. 
vaccination against HBV or HPV, or last for an exceptionally long 
time, e.g. polio eradication. 
 
Finally, the documents address the issue of sensitivity analysis in modelling 
of vaccination programmes. On behalf of the Society for Medical Decision 
Making/ SMDM Duintjer Tebbens et al. [33] highlight the fact that in the 
context of a dynamic economic evaluation model for vaccination programs, 
the choice of methods is especially important when it comes to uncertainty 
and sensitivity analyses. Therefore they compared the results of different 
methods of sensitivity analysis and present the trade-offs in a table. The aim 
was to show that the choice of method should not be made without consider-
ing influence factors such as complexity of the model, number of uncertain 
inputs and desired types of insights from the sensitivity analysis. 
Klein et al. recommend that discount rates in modelling cost-effectiveness of 
vaccination programmes should be varied between 0%-10% in sensitivity 
analysis. Further, they recommend one-way sensitivity analyses for any pa-
rameter which is relevant from a vaccination perspective, probabilistic sensi-
tivity analyses and cost-acceptability-curves in order to examine the influ-
ence of parameter uncertainty on the overall result and scenario-analyses ac-
cording to the specific vaccination programme with and without herd im-
munity effects, varying time horizons, discount rates, etc. in order to exam-
ine the influence of methodological assumptions. 
 
 
discounting of costs and 
benefits 
sensitivity analysis: 
SMDM: dynamic 
economic evaluation 
models specifically 
sensitive to choice of 
methods 
recommendations: 
discount rates 0%-10% 
one-way sensitivity 
analyses 
probabilistic sensitivity 
analyses and cost 
acceptability curves 
scenario analyses 
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4 Limitations of HTA 
HTA can be considered as a scientific approach to support evidence-based 
decision making in healthcare by considering various relevant aspects, 
mainly clinical and economic ones.  
None of the manuals explicitly lists limitations of the method of HTA in the 
form of a proper chapter. The DACEHTA Handbook probably has the most 
self-reflexive approach, listing limitations of single aspects within HTA 
along through the whole book. The main strategy these limitations are faced 
with is one of the main virtues in HTA: transparency; wherever restrictions 
in sub-disciplines are identified the researchers are asked to explain them 
and their impact on the overall result. 
Even though the general topic of ethics is an essential part of every manual, 
in some manuals, some ethical aspects actual do not seem to be judged as 
topics to be analysed, but rather as limitations to be mentioned in HTAs. 
This is the way some manuals particularly deal with the issue of “equity vs. 
equality” [17, 22]. Other manuals’ authors show much more awareness for 
actually working on ethical problems. 
Every sub-discipline has its own limitations where specific standards have 
been developed to deal with them. For example uncertainty in modelling is 
to be addressed by doing sensitivity analyses [18, 30]. 
One important limitation of HTA is mentioned but still far away from 
solved by EUnetHTA. Many results are very hard to transfer into other re-
gional contexts. Sometimes it is because of a simple language barrier that 
the same assessment is done twice or even more often, sometimes there are 
other barriers, often due to context-specific administrative and legal regula-
tions. 
 
hardly any explicit 
limitations in manuals 
ethical topics sometimes 
stated as limitations  of 
HTA instead of separate 
topic  
limitations in sub-
disciplines 
transferability is 
limitation for all types 
of HTA 
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5 Conclusion 
Despite the young age of the discipline and the interdependencies between 
various sub-disciplines, HTA can be considered as a methodology which is 
properly defined in its methodological fundaments. There are clear roots in 
evidence-based medicine, health economics, public health and other fields, 
and the literature is quite consistent about how these disciplines contribute 
to HTA. 
Concerning the different domains in HTA, most detailed standards are 
available for the clinical assessment of technologies. When it comes to eco-
nomic analyses and evaluation of legal, ethical or social issues manuals are 
much less congruent and vary in methodological details provided. 
Manuals deal only to a small extent with standards on modelling. Even 
though there are references and the issue of modelling is often mentioned, 
the degree of standardisation is lower than in the fields of literature search, 
clinical effectiveness and economic evaluation. Only a few documents identi-
fied were dealing with standards in the evaluation of vaccination pro-
grammes. Perspectives are very different and vary from simple data collec-
tion to the question of systematic differences between modelling in vaccina-
tion programmes and other fields of healthcare decision making.
young discipline – well 
established methods 
roots in EbM, health 
economics and public 
health 
clinical domain highly 
standardised 
less standards on 
modelling, very few 
documents on 
vaccination 
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7 Appendix 
7.1 Search strategy 1: The Cochrane Library  
Search Name:   IFEDH 
Comments:       Philipp R. 
Save Date:       2010-12-16 07:26:55.503 
 
ID Search 
#1 MeSH descriptor Technology Assessment, Biomedical explode all 
trees 
#2 MeSH descriptor Decision Support Techniques explode all trees 
#3 modelling 
#4 (#2 OR #3) 
#5 (#1 AND #4) 
 
180 Hits 
7.2 Search strategy 2: Centre for Reviews 
and Dissemination 
 
MeSH Technology Assessment, Biomedical EXPLODE 1 2 
MeSH Decision Support Techniques EXPLODE 1 2 
modeling 
modelling 
#2 OR #3 OR #4 
#1 AND #5 
 
56 Hits 
 
16.12.2010 
 
IFEDH 
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Records identified through 
database searching  
(n = 379) 
Sc
re
en
in
g 
In
cl
ud
ed
 
El
ig
ib
ili
ty
 
Id
en
tif
ic
at
io
n 
Additional records identified 
through other sources  
(n = 41) 
Records after duplicates removed 
(n =  420) 
Records screened 
(n = 420) 
Records excluded 
(n = 271) 
Full-text articles as-
sessed for eligibility 
(n = 149) 
Full-text articles excluded, 
with reasons 
(n = 129) 
background literature n = 
68 
not PICO n = 25 
no study n = 33 
double publication n = 3 
Studies included in 
qualitative synthesis 
(n = 20) 
 
7.3 Examples  
Abbildung 7.3-1: Example for study selection according to PRISMA-Tree  
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Table 7.3-1: Methods of sensitivity analyses recommended in dynamic economic 
evaluation models for vaccination [33] 
 
 
 
 
